These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 34689334)
21. A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines. Zong J; Rojubally A; Pan X; Wolf B; Greenfeder S; Upton A; Gdovin Bergeson J Value Health; 2024 Oct; ():. PubMed ID: 39393564 [TBL] [Abstract][Full Text] [Related]
22. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM. Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703 [TBL] [Abstract][Full Text] [Related]
23. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
24. Trial designs using real-world data: The changing landscape of the regulatory approval process. Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482 [TBL] [Abstract][Full Text] [Related]
25. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Dagenais S; Russo L; Madsen A; Webster J; Becnel L Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524 [TBL] [Abstract][Full Text] [Related]
26. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021. Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814 [No Abstract] [Full Text] [Related]
27. [The application of real-world evidence in drug regulatory decision-making]. Wicherski J; Haenisch B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723 [TBL] [Abstract][Full Text] [Related]
28. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. Zisis K; Pavi E; Geitona M; Athanasakis K J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726 [No Abstract] [Full Text] [Related]
29. Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation. Pulini AA; Caetano GM; Clautiaux H; Vergeron L; Pitts PJ; Katz G Ther Innov Regul Sci; 2021 Jan; 55(1):228-238. PubMed ID: 32857313 [TBL] [Abstract][Full Text] [Related]
30. Use of real-world evidence for oncology clinical decision making in emerging economies. Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583 [TBL] [Abstract][Full Text] [Related]
31. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330 [TBL] [Abstract][Full Text] [Related]
32. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Purpura CA; Garry EM; Honig N; Case A; Rassen JA Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771 [TBL] [Abstract][Full Text] [Related]
33. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model. Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505 [TBL] [Abstract][Full Text] [Related]
34. Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases. Prilla S; Groeneveld S; Pacurariu A; Restrepo-Méndez MC; Verpillat P; Torre C; Gartner C; Mol PGM; Naumann-Winter F; Breen KC; Gault N; Gross-Martirosyan L; Benchetrit S; Aylward B; Stoyanova-Beninska V; O'Donovan M; Straus S; Kjaer J; Arlett P Clin Pharmacol Ther; 2024 Nov; 116(5):1188-1197. PubMed ID: 38962830 [TBL] [Abstract][Full Text] [Related]
35. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S F1000Res; 2018; 7():111. PubMed ID: 30026923 [TBL] [Abstract][Full Text] [Related]
36. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678 [TBL] [Abstract][Full Text] [Related]
37. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics. Bloomfield-Clagett B; Rahman M; Smith K; Concato J Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904 [TBL] [Abstract][Full Text] [Related]
38. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials. Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472 [TBL] [Abstract][Full Text] [Related]
39. The life cycle of vaccines evaluated by the European Medicines Agency. Gräf DD; Westphal L; Hallgreen CE Vaccine; 2024 Aug; 42(21):126186. PubMed ID: 39121512 [TBL] [Abstract][Full Text] [Related]
40. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Sun F; Bedenkov A; Liu BC; Yang J; Xu JF; Ji L; Zhou M; Zhang S; Li X; Song Y; Chen P; Moreno C Pharmaceut Med; 2024 May; 38(3):157-166. PubMed ID: 38573457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]